Health Care • Biotechnology: Pharmaceutical Preparations
$18.67 ▼ -0.36
(-1.92%)
MKT CAP: $21.86B • VOL: 7.25M
52W L $10 52W H $20
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$16
MEDIAN
$21
MEAN
$21
HIGH
$25
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE VTRS TAPE
VTRS // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $22.59 | $21.47 | 2025-02-14 | $16.99 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $23.52 | $22.03 | 2025-02-06 | $17.55 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $21.28 | $20.54 | 2025-01-29 | $17.92 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $19.04 | — | 2025-01-17 | $18.30 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $16.43 | $17.74 | 2025-01-09 | $16.62 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $22.22 | $19.42 | 2024-12-18 | $16.24 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $18.11 | $18.86 | 2024-12-04 | $17.36 | -4.3% | 48% | C |